XLRN Acceleron Pharma Inc

Price (delayed)

$126.58

Market cap

$7.68B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.02

Enterprise value

$7.25B

Sector: Healthcare
Industry: Biotechnology

Highlights

The revenue rose by 49% YoY and by 22% QoQ
XLRN's gross profit is up by 49% year-on-year and by 22% since the previous quarter
XLRN's equity has surged by 96% year-on-year but it is down by 5% since the previous quarter
Acceleron Pharma's net income has decreased by 30% YoY and by 8% from the previous quarter
Acceleron Pharma's EPS has decreased by 17% YoY and by 3.4% from the previous quarter

Key stats

What are the main financial stats of XLRN
Market
Shares outstanding
60.7M
Market cap
$7.68B
Enterprise value
$7.25B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.45
Price to sales (P/S)
67.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.2
Earnings
Revenue
$112.94M
EBIT
-$178.55M
EBITDA
-$168.71M
Free cash flow
-$156.4M
Per share
EPS
-$3.02
Free cash flow per share
-$2.58
Book value per share
$13.39
Revenue per share
$1.86
TBVPS
$14.46
Balance sheet
Total assets
$875.79M
Total liabilities
$64.96M
Debt
$22.43M
Equity
$810.83M
Working capital
$687.79M
Liquidity
Debt to equity
0.03
Current ratio
14.81
Quick ratio
14.3
Net debt/EBITDA
2.57
Margins
EBITDA margin
-149.4%
Gross margin
100%
Net margin
-158.1%
Operating margin
-158.8%
Efficiency
Return on assets
-22.1%
Return on equity
-23.9%
Return on invested capital
-71.2%
Return on capital employed
-21.6%
Return on sales
-158.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XLRN stock price

How has the Acceleron Pharma stock price performed over time
Intraday
2.64%
1 week
7.11%
1 month
3.44%
1 year
29.15%
YTD
-1.06%
QTD
-6.66%

Financial performance

How have Acceleron Pharma's revenue and profit performed over time
Revenue
$112.94M
Gross profit
$112.94M
Operating income
-$179.34M
Net income
-$178.56M
Gross margin
100%
Net margin
-158.1%
The revenue rose by 49% YoY and by 22% QoQ
XLRN's gross profit is up by 49% year-on-year and by 22% since the previous quarter
Acceleron Pharma's net income has decreased by 30% YoY and by 8% from the previous quarter
Acceleron Pharma's operating income has decreased by 22% YoY and by 7% QoQ

Growth

What is Acceleron Pharma's growth rate over time

Valuation

What is Acceleron Pharma stock price valuation
P/E
N/A
P/B
9.45
P/S
67.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.2
Acceleron Pharma's EPS has decreased by 17% YoY and by 3.4% from the previous quarter
XLRN's equity has surged by 96% year-on-year but it is down by 5% since the previous quarter
The stock's price to book (P/B) is 40% more than its 5-year quarterly average of 6.6 but 5% less than its last 4 quarters average of 9.7
The revenue rose by 49% YoY and by 22% QoQ
XLRN's price to sales (P/S) is 28% lower than its 5-year quarterly average of 91.3 and 3.1% lower than its last 4 quarters average of 68.3

Efficiency

How efficient is Acceleron Pharma business performance
XLRN's return on invested capital has dropped by 52% year-on-year but it is up by 15% since the previous quarter
The ROE has grown by 21% YoY and by 7% from the previous quarter
XLRN's return on assets is up by 18% year-on-year and by 6% since the previous quarter
Acceleron Pharma's ROS has increased by 13% YoY and by 12% from the previous quarter

Dividends

What is XLRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XLRN.

Financial health

How did Acceleron Pharma financials performed over time
Acceleron Pharma's total assets has surged by 89% YoY but it has decreased by 6% QoQ
The total liabilities is up by 29% YoY but it is down by 16% QoQ
The debt is 97% lower than the equity
XLRN's equity has surged by 96% year-on-year but it is down by 5% since the previous quarter
The debt to equity has dropped by 50% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.